Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Thu., Aug. 18, 7:09 AM
Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.
| This Slide: #15 of 100 |
Slide #15. Prestige Brands — Hydralyte
Acquirer:
Prestige Brands (NYSE:PBH)
Acquiree:
Hydralyte
Details:
Prestige Brands Holdings, Inc. (NYSE-PBH) today announced the signing of a purchase agreement for the acquisition of Hydralyte in Australia and New Zealand from The Hydration Pharmaceuticals Trust of Victoria, Australia. The acquisition is expected to close, subject to customary closing conditions, during the first quarter of fiscal 2015, which began on April 1, 2014.
Prestige Consumer Healthcare is a holding company. Through its subsidiaries, Co. is engaged in the development, manufacturing, marketing, sales, and distribution of over-the-counter (OTC) health and personal care products. Co. conducts its operations in two reportable segments: North American OTC Healthcare and International OTC Healthcare. Co.'s brands in the North American OTC Healthcare segment include Boudreaux's Butt Paste with products that include various diaper rash treatments and skin protectants. Co.'s brands in the International OTC Healthcare segment include Fess that relieves nasal and sinus congestion due to allergy, hay fever, colds and flu.
PBH SEC Filing Email Alerts Service
Open the PBH Page at The Online Investor »
|
||||||||||||||||||||||||
Open the PBH Page at The Online Investor (in a new window) »
 Free PBH Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
 
|
Buy (3.20 out of 4) 31st percentile
(ranked lower than approx. 69% of all stocks covered)
Analysts' Target Price: PBH Stock Forecast Based on Zacks ABR data; powered by Xignite |
